Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 54Carcinoma, Non-Small-Cell Lung 33Lung Neoplasms 30Breast Neoplasms 29Glioblastoma 23Multiple Myeloma 21Glioma 20Lymphoma 19Pancreatic Neoplasms 17Lymphoma, Large B-Cell, Diffuse 17Carcinoma, Renal Cell 17Urinary Bladder Neoplasms 16Brain Neoplasms 14Sarcoma 13Squamous Cell Carcinoma of Head and Neck 12Rectal Neoplasms 11Neoplasm Metastasis 11Melanoma 11Lymphoma, Non-Hodgkin 11Thyroid Neoplasms 10Ovarian Neoplasms 10Oropharyngeal Neoplasms 10Neuroblastoma 9Mouth Neoplasms 9Medulloblastoma 9Lymphoma, Follicular 9Ependymoma 9Colorectal Neoplasms 9Central Nervous System Neoplasms 9Astrocytoma 9

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sinonasal Squamous Cell Carcinoma × Magnetic Resonance Spectroscopy × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡